Clinical Trial Update: Vorasidenib Expanded Access Program

View source ↗

Summary

Vorasidenib’s expanded access program update notes that vorasidenib has been approved for marketing for glioma recurrence.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma

Drugs mentioned

• Vorasidenib (vorasidenib)

Snippet

Sponsor: Servier | Conditions: Glioma, Recurrence | Status: APPROVED_FOR_MARKETING